Adimmune (4142.TW) Stock Price

Adimmune Price

TWSE·CLOSED
19.20
​
Market closed

Over the last 18 years Adimmune grew revenue by 10.7% annually, reaching 1.40 B TWD. Earnings per share have declined at 11.8% per year over the last 13 years. For Adimmune, the net margin of -17.1% is down versus 2.6% a few years ago. At today's price the dividend yield works out to roughly 2.60%. The payout ratio is around 495% of earnings. The consensus 12-month price target for Adimmune is 35.70 TWD, about 85.9% above where the stock trades today. Of 10 analysts, 0 rate the stock a buy — an overall Sell consensus.

Adimmune stock price

Access this data via the Eulerpool API

Adimmune business model & stock analysis

Adimmune Corp. engages in the manufacturing and sales of influenza vaccine. The company is headquartered in Taichung, Taichung. The company went IPO on 2010-09-29. The firm's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The firm distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.

Frequently asked questions about Adimmune

Analysts currently set an average price target of 35.70 TWD for the Adimmune stock (median: 35.70 TWD), implying +85.9 % versus the latest price. The consensus is based on 10 analyst ratings.

7 analysts currently rate the Adimmune stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Adimmune to generate revenue of 1.52 B TWD and earnings per share of -0.20 TWD.

Converted at the current exchange rate, the Adimmune share trades at 0.54 EUR (19.20 TWD).

The Adimmune share (4142.TW) is listed on 1 stock exchanges, including: TWSE (Taiwan) (4142.TW).

The expected revenue of Adimmune is 1.52 B TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Adimmune is -85.90 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Adimmune is currently -94.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adimmune stock.

The price-to-sales ratio (P/S) of Adimmune is currently 5.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Adimmune stock.

The Eulerpool Quality Score for Adimmune is 2/10.

The ISIN of Adimmune is TW0004142005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Adimmune is 4142.TW. The ticker symbol is used to trade Adimmune shares on the stock exchange.

Fair ValueTerminal
19.78 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
2.54 M TWD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Sep 29, 2010
ISIN
TW0004142005
Cusip
Y0013X105
Market capitalization
8.25 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-94.07
P/Ee 2027
160.00
P/S
P/Se
5.33
EV/EBIT
—
P/B Ratio
1.67
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-3.10 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
2.60 %
Payout Ratio
495.24 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
21.00 %
Last updated Oct 8, 2026, 10:36 PM

Adimmune Peer Group

Adimmune Ticker

TWSE · 4142.TW

Adimmune FIGI

4142:TT (Taiwan Stock Exchange) · BBG001636XY8

All fundamentals and in-depth analysis of Adimmune

Our stock analysis for Adimmune stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adimmune. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.